Classification Overview

Tyrosine Kinase Inhibitors can block the cancer cell from growing and dividing by stopping messages from being passed by chemicals within the cell.

Sort By Distance

Need Help?

Call SparkCures and one of our clinical trial specialists will help answer your questions.

(888) 828-2206

Axitinib (Inlyta)
Axitinib is a small cell tyrosine kinase inhibitor targets that blocks cancer cells from creating new blood vessels. It’s currently FDA approved for use in Renal Cell Carcinoma, and undergoing trials for use in other cancers, including multiple myeloma.
Bosutinib (Bosulif)
Bosutinib is a Tyrosine Kinase Inhibitor that blocks receptors in the cancer cell that promote cell division.
Erlotinib (Tarceva)
Erlotinib is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat non-small cell lung cancer and pancreatic cancer. It is also being studied in the treatment of other types of cancers, including multiple myeloma.